온코크로스

382150KOSDAQ

53.3 / 100

Reference Date: 2026-09-08

Financial Score12.0 / 40

News Sentiment21.3 / 25

Momentum10.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Slightly down 1.6% over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

OncoCross is a company that enhances drug development efficiency through its AI platform 'RAPTOR AI', which matches optimal diseases with therapies based on gene expression and protein data. It is also developing 'RAPTOR AI v2.0' to analyze next-generation modalities like ADC and TPD, and expanding its B2B market through the 'Neo Omics' service.

Number of Employees

40people

Average Salary

75.3M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 15.004.0Point

PBR

3.37Industry Average 1.200.0Point

2.8x industry avg (risky)

ROE

-52.79Industry Average 8.000.0Point

Well below industry avg

Debt Ratio

73.51Industry Average 100.005.0Point

Lower than industry avg (good)

Trend 2023~20253.0 / 10 points

Revenue Growth Rate

3.0 / 3

Avg ▲503.0% (2-year basis)

Operating Profit Growth Rate

0.0 / 3

Avg ▼14.5% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -42.6% (declining, 3yr)

Detailed News Sentiment

2 totalPositive 2Neutral 0Negative 0Average Sentiment Score 85

Positive
온코크로스, ADC 공동개발 진출…AI 분석 넘어 개발 참여
온코크로스가 앱티스와의 ADC 공동개발 계약으로 신약 개발 역량 강화 및 사업 확장 기대.
Positive
온코크로스, 중헌제약과 AI 신약 발굴 R&D 계약…'랩터 AI' 상업...
온코크로스와 중헌제약의 AI 기반 신약 개발 계약 체결로 기술 협력 강화 및 상업화 가능성이 높아져 긍정적 영향 기대.

Detailed Momentum

52-week position1.0Point

Near 52w low (6%, downtrend)

Current 3,455Won52-week high 13,87052-week low 2,685

1-month return3.0Point

1m -1.57% (flat)

Volume trend6.0Point

Volume increasing

Detailed Disclosure

2 totalPositive 0Neutral 2Negative 0

Neutral투자판단관련주요경영사항 (앱티스와 ADC 또는 BsADC 후보물질 공동연구 및 개발 계약 체결)2026-09-01
Neutral반기보고서 (2026.06)2026-08-14